Dr Lalchandani Labs Completes Rights Issue Allotment, Doubles Share Capital

Dr Lalchandani Labs has successfully completed its rights issue allotment, marking a significant milestone in the company's capital expansion strategy. The pathology laboratory company announced the allotment of 43,04,000 fully paid-up equity shares on March 02, 2026, effectively doubling its paid-up share capital through a formal disclosure to BSE Limited under SEBI Listing Regulations. Rights Issue Structure and Timeline The rights issue was initially disclosed on January 20, 2026, with the company proposing to raise ₹430.40 lakhs through the issuance of equity shares. The subscription period commenced on February 04, 2026, and concluded on February 27, 2026, providing eligible shareholders with the opportunity to subscribe to new shares at par value. Parameter: Details Issue Size: 43,04,000 equity shares Face Value: ₹10 per share Issue Price: ₹10 per share Total Amount: ₹430.40 lakhs Subscription Period: February 04 - February 27, 2026 Scrip Code: 541299 ISIN: INE871Z01013 Share Capital Transformation The allotment has resulted in a substantial increase in the company's equity base, with the paid-up share capital witnessing a complete doubling following the successful rights issue completion. The shares were allotted to eligible shareholders and renouncees as per the finalized basis of allotment. Particulars: No. of Equity Shares Total Paid-up Share Capital Pre-Rights Issue: 43,33,068 ₹4,33,30,680 Post-Rights Issue: 86,37,068 ₹8,63,70,680 Board Approval and Regulatory Process The Board of Directors convened on March 02, 2026, from 07:00 PM to 07:55 PM to formalize the allotment decision. The approval process involved consultation with Cameo Corporate Services Limited, serving as the registrar to the issue, and received necessary approvals from BSE Limited as the designated stock exchange for the rights issue. The allotment was conducted in accordance with the Letter of Offer dated January 20, 2026, ensuring compliance with SEBI Listing Regulations under Regulation 30. The formal disclosure was communicated to BSE Limited at Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai, maintaining transparency with the stock exchange. Corporate Governance and Disclosure The disclosure demonstrates the company's commitment to transparency and regulatory compliance, with all relevant information made available on the company's website at lalchandanipathlab.com. The formal communication was digitally signed by Arjan Lalchandani, Managing Director (DIN: 07014579), ensuring proper corporate authorization for this significant capital market transaction. Dr lalchandani labs Limited has announced an extension of its ongoing rights issue closing date following a board meeting held on February 16, 2026. The company has now published newspaper advertisements on February 17, 2026, formally notifying stakeholders about the extension. Rights Issue Extension Details The company's board of directors approved the extension of the rights issue closing date during their meeting on February 16, 2026. The rights issue, which commenced on February 04, 2026, was initially scheduled to conclude on February 20, 2026, but has now been extended by one week to February 27, 2026. Alongside the main issue extension, the company has also extended the deadline for on-market trading in rights entitlements. The trading window, originally set to close on February 17, 2026, has been extended to Tuesday, February 24, 2026. Newspaper Publication and Regulatory Compliance On February 17, 2026, Dr Lalchandani Labs Limited published newspaper advertisements in Financial Express (English - All Edition) and Jansatta (Hindi - All editions) to formally communicate the extension details to all stakeholders. The publication was submitted to BSE Limited with scrip code 541299, signed by Managing Director Arjan Lal Chandani (DIN: 07014579). Revised Rights Issue Timeline The company has provided a comprehensive revised schedule for the rights issue process: Event Date Issue Opening Date Wednesday, February 04, 2026 Last Date for On Market Renunciation of Rights Entitlements Tuesday, February 24, 2026 Issue Closing Date Friday, February 27, 2026 Finalization of Basis of Allotment (on or about) Monday, March 02, 2026 Date of Allotment (on or about) Monday, March 02, 2026 Date of credit (on or about) Wednesday, March 04, 2026 Date of listing (on or about) Thursday, March 05, 2026 Board Meeting and Documentation The board meeting commenced at 01.30 p.m. and concluded at 02:00 p.m. on February 16, 2026. The company has clarified that except for the extension of the issue closing date and consequential changes in the post-issue timeline, there are no other modifications to the Letter of Offer (LOF), Composite Application Form (CAF), or other issue-related documents, all dated January 20, 2026. Rationale for Extension The extension has been granted specifically to facilitate better participation from eligible shareholders and to provide them with adequate time to subscribe to the rights issue. This strategic decision demonstrates the company's commitment to ensuring maximum shareholder participation in the capital raising exercise. The announcement was made in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the information is also available on the company's website at lalchandanipathlab.com. We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better. Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians. As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.